Path to a Cure (PTAC) - Research Grant

The Cystic Fibrosis Foundation offers the Path to a Cure Research Grant to support innovative research aimed at developing therapies for CFTR variants not targeted by existing treatments. Grants can provide up to $150,000 annually for a maximum of three years, contingent on progress reports and fund availability. This program encourages hypothesis-driven proposals, but also accepts innovative tools that may lead to breakthroughs in cystic fibrosis treatments.

About the Cystic Fibrosis Foundation
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care. To achieve this mission, various types of grants and awards are offered to support meritorious research in CF
Program and Award Overview
Path to a Cure: Research Grants are intended to facilitate or enable the development of new information that may contribute to the development of new therapies focused upon repair or replacement of CFTR variants not served by existing small molecule modulators. Applicants seeking to submit proposals focused on topics such as mucociliary clearance and airway hydration, infection and inflammation, or non-lung manifestations of disease should apply through the Research Grant mechanism. Proposals must be hypothesis driven and contain sufficient preliminary data to justify support from the Cystic Fibrosis Foundation. However, proposals that aim to develop tools or reagents that are not typically hypothesis driven but may facilitate research that could lead to a cure will be considered through this mechanism. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH).
Funding of up to $150,000 per year, plus an additional twelve percent (12%) indirect costs may be requested. Awards may be approved for up to a three (3) year period. Funding for Years 2 and 3 are contingent upon submission and approval of a renewal progress report and the availability of funds.